CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$226.98M, lower than 95% of all stocks globally
- PositionGross margin is 8.8%, lower than 95% of its Biotechnology peers (median 67.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.81TKRW2.02B · vs all stocks (USD)
Revenue (TTM)
665.42BKRW479.48M · vs all stocks (USD)
Profit Margin
-12.52%vs Biotechnology peers
Beta
0.9510xvs all stocks
52-Week Change
-21.11%vs all stocks
Market Capitalization
2.81TKRW2.02B · vs all stocks (USD)
Enterprise Value
2.85TKRW2.06B · vs all stocks (USD)
Forward P/E
-39.05xvs Biotechnology peers
Price to Sales (TTM)
4.30xvs Biotechnology peers
Price to Book (MRQ)
1.46xvs Biotechnology peers
Enterprise to Revenue
4.29xvs Biotechnology peers
Enterprise to EBITDA
-49.53xvs Biotechnology peers
Gross Margin
8.81%vs Biotechnology peers
Profit Margin
-12.52%vs Biotechnology peers
Operating Margin
-26.41%vs Biotechnology peers
Return on Assets (TTM)
-3.24%vs Biotechnology peers
Return on Equity (TTM)
-4.34%vs Biotechnology peers
Revenue (TTM)
665.42BKRW479.48M · vs all stocks (USD)
Revenue per Share (TTM)
8.49KKRWUpdated Aug 20, 2026Quarterly Revenue Growth
9.10%vs Biotechnology peers
Gross Profit (TTM)
63.79BKRW45.97M · vs all stocks (USD)
EBITDA (TTM)
-57.64BKRW-41.53M · vs all stocks (USD)
Net Income (TTM)
-83.29BKRW-60.01M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
9.09%vs Biotechnology peers
Operating Cash Flow (TTM)
-2.77BKRW-2.00M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-315.00BKRW-226.98M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
248.65BKRWFY2025 · Dec 31, 2025Revenue
651.37BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
575.44BKRWFY2025 · Dec 31, 2025Gross Profit
75.92BKRWFY2025 · Dec 31, 2025Operating Income
-123.50BKRW-88.99M · vs all stocks (USD)
Pre-tax Income
-85.86BKRWFY2025 · Dec 31, 2025Income Tax Expense
-29.69BKRWFY2025 · Dec 31, 2025Net Income
-56.17BKRWFY2025 · Dec 31, 2025EBIT
-76.46BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-26.80BKRWFY2025 · Dec 31, 2025Research & Development
69.86BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
48.22BKRWFY2025 · Dec 31, 2025Other Operating Expenses
2.13BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
15.67BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
9.40BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-56.17BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
-1.25BKRWFY2025 · Dec 31, 2025Operating Cash Flow
47.79BKRWFY2025 · Dec 31, 2025Free Cash Flow
-83.94BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
105.55BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-56.17BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-6.31BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-19.88BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
130.16BKRWFY2025 · Dec 31, 2025Capital Expenditures
-131.74BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-77.26BKRWFY2025 · Dec 31, 2025Net Acquisitions
-3.61BKRWFY2025 · Dec 31, 2025Purchase of Investments
-349.68BKRWFY2025 · Dec 31, 2025Sale of Investments
198.91BKRWFY2025 · Dec 31, 2025Other Investing Activity
1.62BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-284.50BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
50.05BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
50.84BKRWFY2025 · Dec 31, 2025Shares Outstanding
78.46MSharesUpdated Aug 20, 2026Float Shares
25.96MSharesUpdated Aug 20, 2026% Held by Insiders
68.71%vs all stocks
% Held by Institutions
3.32%vs all stocks
Total Cash (MRQ)
890.16BKRW641.41M · vs all stocks (USD)
Total Cash per Share (MRQ)
11.35KKRWUpdated Aug 20, 2026Total Debt (MRQ)
538.00BKRW387.66M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2659xvs Biotechnology peers
Current Ratio (MRQ)
4.04xvs Biotechnology peers
Book Value per Share (MRQ)
25.80KKRWUpdated Aug 20, 2026Total Assets
2.96TKRW2.13B · vs all stocks (USD)
Total Current Assets
1.25TKRWFY2025 · Dec 31, 2025Total Liabilities
918.29BKRWFY2025 · Dec 31, 2025Total Non-current Assets
1.71TKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
592.05BKRWFY2025 · Dec 31, 2025Total Current Liabilities
326.24BKRWFY2025 · Dec 31, 2025Cash Equivalents
105.55BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
105.55BKRWFY2025 · Dec 31, 2025Other Short-term Investments
800.75BKRWFY2025 · Dec 31, 2025Accounts Receivable
122.01BKRWFY2025 · Dec 31, 2025Inventory
189.20BKRWFY2025 · Dec 31, 2025Accounts Payable
35.29BKRWFY2025 · Dec 31, 2025Short-term Debt
3.75BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-70.00KRWFY2025 · Dec 31, 2025Long-term Debt
466.23BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-60.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
39.22BKRWFY2025 · Dec 31, 2025Retained Earnings
445.26BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
2.04TKRW1.47B · vs all stocks (USD)
52-Week Low
31.80KKRWUpdated Aug 20, 202652-Week High
61.30KKRWUpdated Aug 20, 202652-Week Change
-21.11%vs all stocks
Beta
0.9510xvs all stocks
50-Day MA
36.51KKRWUpdated Aug 20, 2026200-Day MA
44.72KKRWUpdated Aug 20, 2026Avg 10-Day Volume
87.74KSharesUpdated Aug 20, 2026Avg 30-Day Volume
87.80KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-733.00KRWUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 8.8%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 0.09Industry median: 0.67Industry P5: 0.14Peers compared: 261
Financial Health
Altman Z-Score 2.55: grey zoneSignificant
Altman Z-Score: 2.55
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$226.98M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -226,976,019.637Global P5: -219,013,500
Market cap is $2.02B, above the global median of $1.15BNotable
Market cap (USD): 2,023,869,007.103Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Sino Biological Inc.
Tier 1ProductionApproval-Gated PipelineFlowInterface
Syndax Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nuvation Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Caplin Point Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Rapport Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule